New advanced bowel cancer testing service to launch in the UK
New, highly accurate testing service that improves the early-stage detection of bowel cancer with strong clinical validity will be available in the UK within the next few weeks
7 Jan 2026
EDX Medical will be launching its a new, highly accurate testing service, BC95, in the UK within the next few weeks. The service increases the accuracy and sensitivity of testing and includes assessment of hereditary genetic risk for the patient.
It is the most advanced and accurate colorectal testing solution ever to be offered in the UK, with sensitivities in excess of 95% across stages 1 to 4 bowel cancer and approximately 60% sensitivities for very early pre-cancerous adenomas.
The BC95 service comprises a customisable suite of diagnostic tests, tailored to individual patient needs. The testing service uses fecal and blood samples to examine a range of important biomarkers including hereditary genetic status.
The service also includes pre-test counselling for hereditary risk assessment and all data from the various diagnostic procedures are returned to the patient’s designated healthcare provider or doctor for clinical follow-up.
EDX Medical has developed the unique testing service following an agreement with Genomictree of South Korea, to include the first in the UK, epigenetic, colorectal cancer (CRC) biomarker test; EarlyTect® C that measures aberrant SDC2 (Syndecan 2 gene) promoter region methylation, a marker that is frequently observed in early-stage colorectal cancer tissues. It is the most sensitive and accurate epigenetic biomarker test for colorectal cancer currently available on the UK market.
In a cohort of 1124 asymptomatic patients with an overall disease incidence of 1.8%, the test has been shown to have an average sensitivity of 95% for detecting colorectal cancer across stages 1–4, with exceptionally high sensitivity (89.1%) for detecting early-stage cancers (stage 0–2).
The test even detects pre-cancerous advanced adenomatous polyps with a sensitivity of 58.1% making it a particularly useful tool for monitoring those known to have an increased risk of cancer due to hereditary genetics or lifestyle.
The testing service also incorporates currently available test methods such as qFIT, providing additional information allowing clinicians to accurately guide further diagnostic interventions such as colonoscopy or CT colonography.
Dr Mike Hudson, chief executive officer, EDX Medical, commented, “There is growing demand for highly accurate testing solutions for the early detection of bowel and colon cancer in the UK, where late detection of the disease remains a significant cause of premature death. Our new service provides diagnostic tools which enable an assessment of hereditary risk and reliable, early detection when treatment options and outcomes are favorable.”